NCT04262492View on ClinicalTrials.gov

International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants

RecruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2030

Conditions
Antiphospholipid SyndromeThrombosisAnticoagulants Causing Adverse Effects in Therapeutic Use
Interventions
DRUG

Rivaroxaban

Rivaroxaban 10 mg or 15 mg or 20 mg OD Dabigatran 110 mg or 150 mg BID Apixaban 2.5 mg or 5 mg or 10 mg BID

Trial Locations (1)

54500

RECRUITING

Stéphane Zuily, Nancy

All Listed Sponsors
collaborator

International Society on Thrombosis and Haemostasis

UNKNOWN

lead

Stéphane Zuily

OTHER